Henan Taloph Pharmaceutical Stock Co.,Ltd (SHA:600222)

SHA:600222 Revenue

Henan Taloph Pharmaceutical Stock Co.,Ltd had revenue of 394.65M CNY in the quarter ending September 30, 2026, a decrease of -7.02%. This brings the company's total for the last twelve months to 1.70B, down -4.70% year-over-year. In the year 2025, Henan Taloph Pharmaceutical Stock Co.,Ltd had annual revenue of 1.76B, down -9.46%. That makes Henan Taloph Pharmaceutical Stock Co.,Ltd the 15,699th largest company in the world by revenue and 2,836th in China.

• Revenue (ttm): 1.70B
• Revenue Growth: -4.70%
• P/S Ratio: 2.01
• Revenue / Employee: 817.46K
• Employees: 2,084
• Market Cap: 3.42B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Manufacturing of Drug 1.29B 71.2%
• Circulation of medicines and medicinal materials 277.81M 15.3%
• Drug R&D Services 241.51M 13.3%
• Others 4.11M 0.2%

Fiscal year ended Dec 31, 2025 See the full SHA:600222 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.76B	-183.63M	-9.46%
Dec 31, 2024	1.94B	-128.49M	-6.21%
Dec 31, 2023	2.07B	109.21M	5.57%
Dec 31, 2022	1.96B	356.18M	22.20%
Dec 31, 2021	1.60B	187.42M	13.23%

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 12, 2026

Data Sources Report a data error